Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
about
AID and APOBECs span the gap between innate and adaptive immunityNatural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivityAPOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factorsThe restriction factors of human immunodeficiency virusFirst-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3GHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchImpacts of humanized mouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivoThe APOBEC3 family of retroelement restriction factorsCombinatorial RNA-based gene therapy for the treatment of HIV/AIDSEvolutionary conflicts between viruses and restriction factors shape immunitySuppression of APOBEC3-mediated restriction of HIV-1 by VifStructural Insights into HIV-1 Vif-APOBEC3F InteractionCrystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding DomainInsight into the HIV-1 Vif SOCS-box-ElonginBC interactionEnhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinaseMulti-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapyEndogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2nDifferent mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanismsExposure to apoptotic activated CD4+ T cells induces maturation and APOBEC3G-mediated inhibition of HIV-1 infection in dendritic cellsNanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA.Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.Small molecules that inhibit Vif-induced degradation of APOBEC3G.Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restrictionAPOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element.Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized miceLong-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif functionMouse knockout models for HIV-1 restriction factors.Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.Evidence for APOBEC3B mutagenesis in multiple human cancersA single amino acid in human APOBEC3F alters susceptibility to HIV-1 VifSmall-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold.Human APOBEC3 proteins can inhibit xenotropic murine leukemia virus-related virus infectivity.The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase
P2860
Q21131084-2DDF88C8-2ADA-4617-B378-9A37AC7053EDQ21144862-BA091420-069E-493A-B486-6DDB8C6B6368Q24310242-A9FE2494-ABA1-4E48-AA7D-A57C7E43308CQ24321636-5D073BDD-8ACD-4DC7-9BF1-13F35279EE07Q24604018-7DBBBF48-1762-4E34-8F93-18C973E4575DQ24605108-CC7EA366-A7C3-4D4E-A2DB-14225AC2ECF4Q24615552-27AD1385-52DA-4694-AB2C-3892E15B0668Q26746070-20F0231C-360C-4B50-A82C-C41D89503C82Q26851152-A798D41B-6531-4EB0-8EA5-6766F3FA1E2AQ26862780-E5513607-94E2-4A85-AD42-925599925738Q26866145-22AD8D58-D60B-4792-A2E3-05A3CBF1B50CQ27022032-E243BD6A-7C67-4D67-B7D8-FB60CC61BDC2Q27025150-07475467-D745-4627-A0C6-08063E21899AQ27321018-86FC9E95-47F7-4BDB-86B4-E142DDA1470CQ27678176-CE7B0163-9D84-47C2-B369-135F68ABAFE4Q27680599-9E637B56-FF7B-4963-BF87-EEDEA675D60DQ28235509-2558AC18-C973-4BA9-B1EE-D2007F82D9C5Q28480578-4F9492F4-C23E-41B9-92DE-3CF564A977AAQ28481286-65E2842A-FBF4-4C8B-927D-10FC13BD7FB7Q28541264-35EC8B09-7107-4550-AD78-9FDFD0F215CFQ28743559-E06326C4-A684-499E-B43E-AAC60542BEAEQ30525163-E5028BC2-7AB9-43C3-B53C-EAB6F7A08656Q33602923-D7B62299-53FF-4C51-B4C1-66DF763A35A1Q33651576-014B9156-0303-48F5-B49D-445AA63C79CFQ33857983-A639F74A-A528-4658-A37C-6BA6F1829FEAQ34012844-AC9F5278-73AB-4752-99CB-55AF5B32AF30Q34020228-9788F72E-96AF-4C51-8F30-B5F9B5686047Q34037651-0048D5A7-D7B5-461B-9612-4F915C4904C2Q34045987-54DEC858-7669-4735-A568-04E5B466C2E9Q34052968-76F3A780-35FD-4377-9D25-F85A7C74AF53Q34120265-F9FAD719-45F0-43F7-B8F6-3A511E6C55E8Q34120768-8B096DB1-3EAA-49A3-8EF2-E032AC4CD284Q34161853-8039FD0B-C037-4960-A78F-52FC059D0837Q34242229-C4096EEE-7A5E-4933-AC35-6695FE1CC9F2Q34357412-33BA6F57-8CB5-4C62-AC54-EBE4FE257C61Q34412675-5EDF75B1-F9F5-41D7-A379-F50488CFCC36Q34488163-D38DF820-FB45-42E0-9679-B1C44A4D4907Q34558286-E7F804EB-3D16-4A6F-A14A-8BAB8CAD64CDQ34612416-29DAC908-EC93-4826-9F68-ABBF839C0738Q34695564-CC99E290-3992-4C62-A2E2-82E798DD84FA
P2860
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interactions of host APOBEC3 r ...... implications for therapeutics.
@ast
Interactions of host APOBEC3 r ...... implications for therapeutics.
@en
type
label
Interactions of host APOBEC3 r ...... implications for therapeutics.
@ast
Interactions of host APOBEC3 r ...... implications for therapeutics.
@en
prefLabel
Interactions of host APOBEC3 r ...... implications for therapeutics.
@ast
Interactions of host APOBEC3 r ...... implications for therapeutics.
@en
P2860
P1476
Interactions of host APOBEC3 r ...... implications for therapeutics.
@en
P2093
John S Albin
P2860
P356
10.1017/S1462399409001343
P577
2010-01-22T00:00:00Z